The startup develops dihydroorotate dehydrogenase inhibitors aimed at improving treatment outcomes for patients with acute myeloid leukemia. By targeting this specific enzyme, the company seeks to enhance patient survival rates in a disease characterized by poor prognosis and limited treatment options.
Funding
Funding not disclosed
Founders
Product
Problem
Acute Myeloid Leukemia (AML) is a hematologic malignancy with poor prognosis and limited effective treatment options. Current therapies often fail to achieve durable remissions, leading to relapse and reduced overall survival rates for patients. The need for novel therapeutic strategies that can overcome drug resistance and improve patient outcomes in AML remains urgent.
Solution
This startup is developing a novel class of dihydroorotate dehydrogenase (DHODH) inhibitors designed to selectively target and disrupt the metabolic pathways essential for AML cell survival and proliferation. By inhibiting DHODH, the company aims to block de novo pyrimidine biosynthesis, leading to cell cycle arrest and apoptosis in AML cells. The inhibitors are designed to overcome resistance mechanisms associated with existing AML therapies and offer a more targeted approach to cancer treatment. Preclinical studies suggest that these inhibitors can synergize with existing chemotherapeutic agents, potentially improving treatment efficacy and reducing the risk of relapse. The company's approach seeks to provide a more effective and less toxic treatment option for AML patients, ultimately improving survival rates.
Target Audience
The primary target audience includes hematologists, oncologists, and patients with Acute Myeloid Leukemia (AML) who are seeking more effective and less toxic treatment options.
Features
- Potent and selective inhibition of dihydroorotate dehydrogenase (DHODH)
- Designed to overcome drug resistance mechanisms in AML cells
- Induces cell cycle arrest and apoptosis in AML cells
- Synergistic activity with existing chemotherapeutic agents
- Oral bioavailability for convenient administration
- Formulation optimized for enhanced drug delivery and reduced off-target effects
- Preclinical data demonstrating efficacy in AML cell lines and xenograft models